skip to main content

Pioglitazone heart failure — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardEndocrine TherapeuticsPioglitazone heart failureGPhC CRA

A patient with type 2 diabetes and symptomatic heart failure presents a new prescription for pioglitazone. They report worsening ankle oedema and breathlessness this week. What should the pharmacist do?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CWithhold pioglitazone and urgently query symptomatic heart failure

Withhold pioglitazone and urgently query symptomatic heart failure: Pioglitazone causes fluid retention and is contraindicated in current or previous heart failure; worsening oedema and breathlessness need clinical assessment before any supply. Supply low-dose pioglitazone and add a diuretic if weight rises: Adding a diuretic does not neutralise a contraindicated thiazolidinedione in symptomatic heart failure. Defer one week and restart pioglitazone after oedema improves: Transient symptom improvement would not remove the underlying heart-failure contraindication. Supply pioglitazone with daily weights and a two-week review: Monitoring after exposure is inadequate when the medicine is contraindicated and symptoms are already worsening. Replace pioglitazone with another thiazolidinedione: Fluid retention and heart-failure risk are class concerns and substitution requires authorised review.

Reference: BNF: pioglitazone: https://bnf.nice.org.uk/drugs/pioglitazone/